🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Fluticasone furoate (FF) (100 mcg)

Found 48 matching trials

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

PHASE1

This will be a randomized, double-blind, single-dose, three-period balanced...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-11-08

Trial ID

NCT01725685

Treatments Being Tested

FF 400 mcg UMEC 500 mcg FF/UMEC 400/500 mcg

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

PHASE2

This is a randomized, placebo-controlled, 2-period crossover, escalating re...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-02-09

Trial ID

NCT02991859

Treatments Being Tested

Fluticasone furoate (FF) Dry Powder Inhaler Fluticasone propionate (FP) Dry Powder Inhaler Budesonide (BUD) Turbuhaler Placebo (ELLIPTA or DISKUS)

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

PHASE1

This is an open-label, five- period, cross-over, randomized, single dose, s...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-10-28

Trial ID

NCT02218723

Treatments Being Tested

FF UD-DPI FF ELLIPTA DPI

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

PHASE4

This is a multi-center, randomized, double-blind, parallel-group study. The...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-01-28

Trial ID

NCT01957150

Treatments Being Tested

Fluticasone Furoate/Vilanterol Vilanterol

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

PHASE3

This is a Phase III, multicenter, randomized, double-blind, stratified, par...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-09-20

Trial ID

NCT01686633

Treatments Being Tested

Fluticasone Furoate/ Vilanterol 200/25 mcg Fluticasone Furoate/ Vilanterol 100/25 mcg Fluticasone Furoate 100 mcg

Relovair PD PK in Chinese Healthy Subjects

PHASE1

In this study, fluticasone furoate (FF) and vilanterol (VI) in different do...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-12-05

Trial ID

NCT01711463

Treatments Being Tested

Fluticasone Furoate/Vilanterol Placebo

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

Previous Next